Psychotropic agents and uses thereof
Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain.
1. A compound having a structure of Formula I:
including pharmaceutically acceptable salts and stereoisomers thereof, wherein:
R 1 is
and
X and Z are the same or different and independently selected from the group consisting of hydrogen, methyl, and alkyl; with the proviso that at least one of X and Z is not hydrogen.
2. The compound of claim 1 , wherein the compound is a stereoisomer having a structure of Formula I-S:
including pharmaceutically acceptable salts thereof.
3. The compound of claim 1 , wherein X is H.
4. The compound of claim 3 , wherein X═H and Z═CH 3 .
5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
6. A method of antagonizing dopamine and/or serotonin and/or α2 receptor in a subject comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , either individually or in combination with other CNS active agents.
7. A method of treating schizophrenia in a subject comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , either individually or in combination with other CNS active agents.
8. The method of claim 6 , wherein the method further comprising administering to the subject a therapeutically effective amount of another medication.
9. The method of claim 6 , wherein the disorder or condition is selected from the group consisting of depression, bipolar disorder, Tourette's syndrome, Schizoaffective disorder, Parkinson's psychosis, Alzheimer's psychosis, oppositional defiant disorder, personality disorder, childhood schizophrenia, dysthymia, treatment resistant schizophrenia, chronic fatigue syndrome, and negative symptoms of schizophrenia.
10. The method of claim 6 , wherein the serotonin receptor is 5-HT 2a receptor.
11. The method of claim 6 , wherein the α2 receptor is selected from the group consisting of α2A receptor, α2B receptor, α2C receptor, and combinations thereof.
12. The compound of claim 1 , wherein the compound is a stereoisomer having a structure of Formula I-R:
including pharmaceutically acceptable salts thereof.